Clinical trial
Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus
NCT00135083 · Sanofi, Industry · Completed
Key facts
| NCT number | NCT00135083 |
|---|---|
| Title | Variable Bolus Regimen 1-2-3 for Type 2 Diabetes Mellitus |
| Official title | One Versus Two Versus Three Daily Rapid-acting Insulin Injections of APIDRA (Insulin Glulisine) as add-on to Lantus® and Oral Sensitizer Basal Therapy in Type 2 Diabetes: a Multicenter, Randomized, Parallel, Open-label Clinical Study |
| Lead sponsor | Sanofi, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Diabetes Mellitus, Type 2 |
| Intervention type | Drug |
| Interventions | insulin glulisine |
| Enrollment | 347 |
| Start date | Aug 1, 2004 |
| Completion | Nov 1, 2007 |
| First posted | Aug 25, 2005 |
| Last update posted | Jan 11, 2011 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: